The Treatment That Halved Overdose Deaths Is Under Attack From the People Supposed to Protect It

On April 24, 2026, the Substance Abuse and Mental Health Services Administration sent a two-page “Dear Colleague” letter to addiction treatment programs across the country. It didn’t announce regulatory changes. No funding was revoked. The letter’s language was careful — supportive, even — about the importance of evidence-based care. But buried in the third paragraph was a phrase that addiction medicine specialists have been parsing ever since:

“Medications are part of the pathway to long-term recovery…not as a default sentence to life-long medication use.”

The letter was almost certainly written by someone who thought it struck a reasonable balance. It is, in practice, a declaration of war against the scientific consensus on how to treat opioid use disorder — and against the approximately two million Americans whose daily stability depends on buprenorphine or methadone. The phrase “life-long medication use” is framed as something to escape, a sentence to be served out. The word “sentence” is not accidental. It is the entire argument.

What Long-Term Actually Means for Two Million People

Buprenorphine is not Percocet. This is a distinction that addiction specialists have been making for thirty years with increasing exhaustion, because the confusion is not incidental — it is the ideological load-bearing wall of every effort to restrict medications for opioid use disorder.

Here is what long-term buprenorphine maintenance actually does, pharmacologically: it binds to opioid receptors with high affinity and low intrinsic activity, preventing withdrawal, blocking the reinforcing effects of illicitly obtained opioids, and producing no meaningful euphoria at therapeutic doses. It is a partial agonist stabilizer. Its clinical effect is not sedation or impairment. It is, for most people, indistinguishable from nothing — which is precisely the point. You feel normal. You function. You do not spend your cognitive and emotional energy managing an acute craving or calculating how many hours until withdrawal begins.

The evidence on this is not contested. A 2020 study in The Lancet found that MOUD reduced all-cause mortality by 68% compared with no treatment. A Cochrane review covering more than 35 randomized controlled trials found that buprenorphine-naloxone reduced heroin use by more than 50%. SAMHSA’s own data — the data the agency publishes annually — shows that the single strongest predictor of opioid overdose death is discontinuation of MOUD. Not drug supply changes. Not poverty. Not prior overdose history. The single strongest predictor is: stopped the medication.

For people whose mu-opioid receptors were sensitized by years of use, abrupt discontinuation of MOUD triggers a neurological crisis — sweating, nausea, insomnia, the crushing affective dysphoria that patients describe as the worst they have ever felt — that lasts weeks and peaks at the exact moment when craving is at its highest and the illicit drug supply is at its most contaminated. The clinical term for what follows, statistically, is relapse. The clinical term for what follows relapse, often, is overdose. SAMHSA has the numbers on this. So does the CDC. So does every emergency room physician who has treated a patient in the week after they stopped their Suboxone.

The word “sentence” applied to a medication that interrupts this cycle is, to put it plainly, backwards. It inverts the causation. The sentence is the disease. The medication is the release.

Yngvild Olsen directed SAMHSA’s Center for Substance Abuse Treatment until 2025. She watched the Dear Colleague letter land from outside the building. When STAT News reached her in June, she did not soften her assessment: “The winds clearly have shifted away from thinking about evidence-based ways.” She did not say the winds had changed direction. She said they had shifted away from evidence.

The Man Now Running the Legal Architecture

To understand where the SAMHSA letter came from, it helps to know who is now the top lawyer at the Department of Health and Human Services.

To understand where the SAMHSA letter came from, it helps to know who is now the top lawyer at the Department of Health and Human Services.

Michael Stuart was confirmed as HHS General Counsel in October 2025. Before that, he was a state lawmaker in West Virginia — a state that has one of the highest rates of opioid use disorder in the country, and one of the worst access rates for MOUD. Stuart is best known in the addiction policy community for a single legislative effort during his time in the West Virginia statehouse: a bill to ban methadone clinics from operating in the state. The bill did not pass. But Stuart’s position — that methadone treatment represents a kind of failure, that it substitutes one addiction for another — was documented across floor speeches and committee testimony.

He is now the senior legal counsel for the department that regulates every methadone clinic in the United States. He oversees SAMHSA’s legal framework. He is in the room when guidance is drafted.

Stuart did not write the Dear Colleague letter. His name is not on it. But the letter arrived five months after his confirmation, and the phrase “not as a default sentence to life-long medication use” reads, to anyone who has followed the internal debates in addiction medicine for more than a decade, like language shaped by someone who believes the sentence is real — who believes that buprenorphine maintenance is not treatment but moral compromise, and that the goal of treatment is to eventually be free of medication rather than to be alive and functional for the rest of one’s life.

Robert F. Kennedy Jr., who took office as HHS Secretary in February 2025, is in recovery himself. In April 2025, speaking at the Rx Summit in Nashville, he said explicitly: “We need Suboxone, we need methadone, we need naltrexone, we need Narcan.” That statement was greeted as a reassurance by the addiction medicine community. A year later, the department Kennedy runs issued a letter telling clinicians these medications are not meant to be “life-long.” The gap between those two positions is where policy happens. It is a gap that costs lives.

The Bill With No Co-Sponsors That Still Tells You Everything

In September 2025, Rep. Erin Houchin (R-Indiana) introduced H.R. 5629, a bill with a specific target: the 2024 SAMHSA final rule that had liberalized access to MOUD. The rule was, by the standards of addiction medicine history, historic. After years of rulemaking, it had eliminated the requirement that patients must demonstrate they have been addicted for at least one year before beginning methadone treatment. It allowed telehealth evaluation for methadone and buprenorphine prescriptions. It removed requirements that patients in early treatment visit a methadone clinic in person every day.

These were not fringe positions. The one-year addiction requirement had been widely recognized by clinicians as irrational — it required that a disease progress before treatment could begin, a standard applied to no other medical condition. The daily in-person visit requirements, in states where methadone clinics are scarce, functioned as geographic bans for anyone without a car, a flexible work schedule, or proximity to a clinic. Telehealth MOUD had, during the COVID public health emergency, expanded treatment access dramatically — particularly to rural populations and to people of color who faced systemic barriers to clinic-based care.

Houchin’s bill would restore all of it: the one-year requirement, the daily visits, the telehealth prohibition. In March 2026, a coalition that included the American Society of Addiction Medicine, the American Academy of Family Physicians, and the American Psychiatric Association sent a formal letter to Congress. Its language was precise: “If enacted as currently drafted, the bill would result in more opioid overdoses.”

That is not a prediction about the future. It is a statement about what the clinical evidence shows has happened — and what will happen again — when these requirements are in place. The organizations signing that letter have collectively treated hundreds of thousands of patients with OUD. They know the shape of what comes next.

It is a statement about what the clinical evidence shows has happened — and what will happen again — when these requirements are in place.

As of June 2026, H.R. 5629 has no co-sponsors. No committee has scheduled a hearing. By the standard metrics of legislative traction, it is going nowhere.

But a bill’s lack of momentum does not make it inconsequential. It is a window — into what a portion of the Republican caucus believes about addiction treatment, and into what the administration is watching to gauge Congressional appetite for further administrative restriction. The Dear Colleague letter, read alongside the Houchin bill, reads as a clearing of ideological ground: an attempt to normalize the view that MOUD is a transitional tool, not a permanent treatment, so that the next administrative action arrives in a landscape that has already accepted that premise.

What the People on These Medications Actually Hear

When two million people take a medication every morning, the policy discourse around that medication is not abstract to them. It is a background frequency — the question of whether it will still be available, still be covered, still be supported by the professional and regulatory structures they depend on — playing beneath everything else.

For most of the people on buprenorphine or methadone maintenance, the medication represents the moment the cycle stopped. Not the moment they achieved some ideological definition of sobriety, but the moment the neurological loop of use, withdrawal, and compulsive return to use became, for the first time, interruptible. The medication did not end craving — anyone on long-term MOUD will tell you that craving does not simply disappear. What the medication did was create enough stability that craving became manageable. That is both a precise pharmacological description and an accurate description of what recovery feels like from the inside of it.

The ASAM public comment period for the 2024 SAMHSA rule collected more than 3,000 statements from patients. A recurring pattern across those statements: the fear — not the side effects, not the cost, but the specific fear — that someone with a policy position and a philosophical framework would eventually decide that long-term maintenance was inappropriate, and that the stability patients had built their lives on would be administratively withdrawn. That fear, documented in thousands of written statements submitted to the federal record, was not paranoia. The Dear Colleague letter of April 24, 2026, confirms that it is structural.

The Decline Was Not an Accident

On June 17, 2026, the CDC released preliminary data showing 69,147 drug overdose deaths for the 12 months ending January 2026 — a 13.2% decline from the prior year, and the steepest sustained drop in overdose mortality the United States has ever recorded. The decline from the 2022 peak of 107,941 deaths represents more than 38,000 people still alive who would not have been alive had the 2022 rate held. That is not a statistical artifact. That is a city.

The decline did not happen because the drug supply got safer. Illicitly manufactured fentanyl still accounts for roughly 70% of all overdose deaths. Xylazine, nitazenes, and other adulterants have made the supply more dangerous in certain regions. What changed was access: naloxone distribution expanded dramatically, harm reduction programs reached more people, and — most consequentially — MOUD coverage expanded across Medicaid, telehealth prescribing, and low-barrier clinic models that the 2024 SAMHSA rule was specifically designed to enable.

The Dear Colleague letter, the Michael Stuart appointment, and the Houchin bill are not three separate policy events. They are three arguments in the same debate — about whether the treatment that produced the most significant reduction in overdose deaths in American history is something the government should promote or something it should help people off of.

David Fiellin, who directs the Yale Program in Addiction Medicine, has written that the framing of medication maintenance as morally suspect — or, in SAMHSA’s language, as a “sentence” — reflects not medical judgment but cultural discomfort with the idea that some conditions require indefinite pharmacological management. “We don’t tell people with hypertension that long-term antihypertensives represent a failure to achieve wellness,” he has observed. The distinction, when pressed, is not clinical. It is moral.

“We don’t tell people with hypertension that long-term antihypertensives represent a failure to achieve wellness,” he has observed.

The 38,000 people who are still alive in 2026, in part because they stayed on their medications — they did not stay alive because of a policy philosophy. They stayed alive because the medication worked.

The administration’s current position is that medication is fine, as long as it isn’t long-term. The clinical literature has a word for what happens when MOUD is not long-term. It calls it discontinuation. Then it calls it withdrawal. Then, in a supply saturated with fentanyl, it calls it a preventable death. SAMHSA has the data on this. It always has.

---

This story is part of Rize’s ongoing coverage of opioid use disorder treatment policy. For more on how federal funding changes are affecting treatment access in Arizona, see our Policy & Funding coverage.